TheStreet Quant Ratings rates Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) as a sell. The company’s weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares after opening at $7.48 on last trade day and at the end of the day closed at $8.17. Company price to sales ratio in past twelve months was calculated as 33.27 and price to cash ratio as 5.15. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) showed a positive weekly performance of 0.49%.
Equities research analysts at Jefferies Group on Mar 10th, 2014 increased their price objective on shares of Rigel Pharmaceuticals (NASDAQ:RIGL) from $6.00 to $10.00 in a research note issued to investors on Thursday, ARN reports. The firm currently has a “buy” rating on the stock. Jefferies Group’s target price indicates a potential upside of 121.24% from the company’s current price. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shares advanced 15.46% in last trading session and ended the day on $4.63. RIGL return on equity ratio is recorded as -37.80% and its return on assets is 3.00%. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) yearly performance is -35.30%.
Research analysts at MLV & Co. boosted their price objective on shares of Agenus (NASDAQ:AGEN) from $9.00 to $11.00 in a report released on Friday, Analyst Ratings.Net reports. The firm currently has a “buy” rating on the stock. MLV & Co.‘s target price would indicate a potential upside of 169.61% from the stock’s previous close. Agenus Inc (NASDAQ:AGEN) shares moved up 5.88%in last trading session and was closed at $4.32, while trading in range of $4.16 – $4.53. Agenus Inc (NASDAQ:AGEN) year to date (YTD) performance is 63.64%.
CEL-SCI Corporation (NYSEMKT:CVM) announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection) has activated its first U.S. clinical trial expansion site at 21st Century Oncology in Greenville, North Carolina. The trial is already active in dozens of hospitals and clinical centers in 12 countries. CEL-SCI Corporation (NYSEMKT:CVM) weekly performance is 8.51%. On last trading day company shares ended up $1.53. CEL-SCI Corporation (NYSEMKT:CVM) distance from 50-day simple moving average (SMA50) is 48.63%. Analysts mean target price for the company is $7.00.